NCT03074513View on ClinicalTrials.gov

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

March 3, 2017

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Appendix AdenocarcinomaHuman Papillomavirus-Related Anal Squamous Cell CarcinomaHuman Papillomavirus-Related Cervical Squamous Cell CarcinomaHuman Papillomavirus-Related Squamous Cell Carcinoma of the PenisHuman Papillomavirus-Related Vulvar Squamous Cell CarcinomaNeuroendocrine CarcinomaPancreatic Neuroendocrine TumorRecurrent Merkel Cell CarcinomaRecurrent Nasopharynx CarcinomaRecurrent Peritoneal Malignant MesotheliomaRecurrent Pleural Malignant MesotheliomaStage III Merkel Cell Carcinoma AJCC v7Stage III Nasopharyngeal Carcinoma AJCC v7Stage III Pleural Malignant Mesothelioma AJCC v7Stage IV Merkel Cell Carcinoma AJCC v7Stage IV Nasopharyngeal Carcinoma AJCC v7Stage IV Pleural Malignant Mesothelioma AJCC v7Stage IVA Nasopharyngeal Carcinoma AJCC v7Stage IVB Nasopharyngeal Carcinoma AJCC v7Stage IVC Nasopharyngeal Carcinoma AJCC v7Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
DRUG

Atezolizumab

Given IV

BIOLOGICAL

Bevacizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER